Prof. Fengzhi Feng 冯凤芝
Chief Physician, Professor
Gynecologic Oncology, Peking Union Medical College Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical, chemotherapy, targeted, and immunotherapy for gynecologic tumors, including ovarian, endometrial, and cervical cancers, gestational trophoblastic disease, ovarian cysts, uterine fibroids, and intravenous leiomyomatosis.
Dr. Feng is a Chief Physician, Professor, and doctoral supervisor. Since September 1993, Dr. Feng has worked in the Department of Obstetrics and Gynecology at Peking Union Medical College Hospital. Clinical expertise includes diagnosis, surgery, and chemotherapy for benign and malignant gynecologic tumors, with extensive experience in diagnosing and treating gestational trophoblastic disease.
Name order: in Chinese the family name comes first (Feng Fengzhi). Papers usually list the name as Fengzhi Feng or Feng F.
Selected publications
89 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- World J Surg Oncol, 2026 (senior author): Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study using inverse probability of treatment weighting. PubMed 41715093
- Ther Adv Med Oncol, 2025 (senior author): Pretreatment circulating tumor DNA and tissue genomic profiling concordance in ovarian cancer: a prospective observational study of influencing factors and clinical implications. PubMed 41362586
- Gynecol Oncol, 2025 (senior author): Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105). PubMed 40616958
- Int J Womens Health, 2025 (senior author): Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial. PubMed 39931671
- Int J Gynecol Cancer, 2024 (senior author): Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study. PubMed 38658019
- J Ovarian Res, 2023 (senior author): Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response. PubMed 37993916
- J Gynecol Oncol, 2023 (senior author): Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis. PubMed 36998223
- Int J Gynecol Cancer, 2023 (senior author): Endometrial clear cell carcinoma with non-gestational choriocarcinoma differentiation: use of rapamycin maintenance. PubMed 37277138
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion